» Articles » PMID: 33139983

Primary Neuroendocrine Carcinoma of the Breast: a Rare Presentation and Review of the Literature

Overview
Date 2020 Nov 3
PMID 33139983
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Primary neuroendocrine carcinoma of the breast (NEBC) is a very rare occurrence accounting for less than 0.1% of all breast cancers. Typically, the tumor presents with ER- and PgR-positive and HER-2-negative status. Despite its luminal type, NEBC is associated with a more aggressive clinical course and poorer prognosis compared to the other types of invasive breast cancer. Clinical and radiological findings are nonspecific. The most common clinical manifestation is a palpable mass whereas in mammography the tumor most commonly appears as a round or oval mass without spiculated margins. Herein, a very rare case of NEBC is described in an asymptomatic patient who presented with an area of architectural distortion and the presence of microcalcifications that was incidentally detected on a screening mammography. A review of the literature has also been conducted. The diagnosis of NEBC requires a thorough investigation to exclude the possibility of a metastatic neuroendocrine tumor from another site because the two entities require different treatment approaches. Due to the rarity of the disease, the optimal therapeutic approach has not been clearly defined. Surgical resection is the mainstay of treatment. Further research is needed to better understand the molecular characteristics of NEBC and identify novel targeted therapies.

Citing Articles

Primary neuroendocrine tumor of the breast: A case report.

Ju H, Liu M Oncol Lett. 2024; 29(2):79.

PMID: 39655273 PMC: 11626422. DOI: 10.3892/ol.2024.14825.


CDK4/6 and aromatase inhibitors as first-line treatment in metastatic high-grade neuroendocrine carcinoma of the breast: A case report.

Zouki D, Kardara V, Ioannou S, Arvanitou E, Exarchos K, Gkikas K Clin Case Rep. 2024; 12(7):e9180.

PMID: 39021492 PMC: 11252434. DOI: 10.1002/ccr3.9180.


Clinicopathological Characteristics and Prognostic Profiles of Breast Carcinoma with Neuroendocrine Features.

Qiu Y, Dai Y, Zhu L, Hao X, Zhang L, Bao B Life (Basel). 2023; 13(2).

PMID: 36836889 PMC: 9967167. DOI: 10.3390/life13020532.


Case Report: Extensive Tumor Profiling in Primary Neuroendocrine Breast Cancer Cases as a Role Model for Personalized Treatment in Rare and Aggressive Cancer Types.

Schaffrin-Nabe D, Schuster S, Tannapfel A, Voigtmann R Front Med (Lausanne). 2022; 9:841441.

PMID: 35721079 PMC: 9203716. DOI: 10.3389/fmed.2022.841441.


Primary neuroendocrine carcinoma of the breast with paraneoplastic thrombocytosis; a rare case report.

Kherbek H, Skef J, Kherbek S, Abdulrahman S, Alshehabi Z, Zahlouk N Ann Med Surg (Lond). 2022; 77:103664.

PMID: 35638022 PMC: 9142635. DOI: 10.1016/j.amsu.2022.103664.

References
1.
Alva K, Tauro L, Shetty P, Saldanha E . Primary neuroendocrine carcinoma of the breast: A rare and distinct entity. Indian J Cancer. 2016; 52(4):636-7. DOI: 10.4103/0019-509X.178432. View

2.
Vranic S, Palazzo J, Sanati S, Florento E, Contreras E, Xiu J . Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast. Clin Breast Cancer. 2018; 19(2):131-136. DOI: 10.1016/j.clbc.2018.09.001. View

3.
Nawawi O, Ying Goh K, Rahmat K . A rare case of primary infiltrating neuroendocrine carcinoma of the breast. Iran J Radiol. 2013; 9(4):212-6. PMC: 3569554. DOI: 10.5812/iranjradiol.8517. View

4.
Soe A, Joseph G, Guevara E, Xiao P . Primary Neuroendocrine Carcinoma of the Breast Metastatic to the Bones, Which Chemotherapy?. Breast J. 2017; 23(5):589-593. DOI: 10.1111/tbj.12800. View

5.
Locurto P, Antona A, Grillo A, Ciulla A, Martorana S, Cipolla C . Primary neuroendocrine carcinoma of the breast A single Center experience and review of the literature. Ann Ital Chir. 2016; 87. View